Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: State-of-the-science

Expert Review of Anticancer Therapy

Volumn 12, Issue 12, 2012, Pages 1571-1577

  Porta, Camillo ^a,b   Sabbatini, Roberto ^b,c   Procopio, Giuseppe ^b,d   Paglino, Chiara ^a,b   Galligioni, Enzo ^e   Ortega, Cinzia ^b,f  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b Italian Nephro Oncology Group   (Italy)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

^e SANTA CHIARA HOSPITAL   (Italy)

^f CANDIOLO CANCER INSTITUTE   (Italy)

Author keywords

molecular mechanism; primary; refractory; renal cell carcinoma; resistance; tyrosine kinase inhibitor

Indexed keywords

AXITINIB; EVEROLIMUS; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VON HIPPEL LINDAU PROTEIN;

ANTIANGIOGENIC THERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; HUMAN; KIDNEY CARCINOMA; KIDNEY METASTASIS; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU GENE;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DRUG RESISTANCE, NEOPLASM; HUMANS; KIDNEY NEOPLASMS; RECEPTOR PROTEIN-TYROSINE KINASES; TOR SERINE-THREONINE KINASES;

EID: 84871514484     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.12.81     Document Type: Review

References (36)

1. Cohen HT, McGovern FJ. Renal-cell carcinoma. N. Engl. J. Med. 353(23), 2477-2490 (2005
2. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann. Oncol. 18(3), 581-592 (2007
3. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N. Engl. J. Med. 335(12), 865-875 (1996
4. Escudier B, Eisen T, Stadler WM et al.; TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N. Engl. J. Med. 356(2), 125-134 (2007
5. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon a in metastatic renal-cell carcinoma. N. Engl. J. Med. 356(2), 115-124 (2007
6. Escudier B, Pluzanska A, Koralewski P et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind Phase III trial. Lancet 370(9605), 2103-2111 (2007
7. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356(22), 2271-2281 (2007
8. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma; a double-blind, randomized, placebo-controlled, Phase III trial. Lancet 372(9637), 449-456 (2008
9. Sternberg CN, Davis ID, Mardiak J et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized Phase III trial. J. Clin. Oncol. 28(6), 1061-1068 (2010
10. Rini BI, Escudier B, Tomczak P et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomised Phase 3 trial. Lancet 378(9807), 1931-1939 (2011
11. Porta C, Paglino C, Imarisio I. Sequencing tyrosine kinase inhibitors or immediately switching to mTOR inhibitors in advanced kidney cancer: A critical review. Eur. J. Clin. Med. Oncol. 2, 67-72 (2011
12. Heng DY, Mackenzie MJ, Vaishampayan UN et al. Primary anti-vascular endothelial growth factor (VEGF)- refractory metastatic renal cell carcinoma: Clinical characteristics, risk factors, and subsequent therapy. Ann. Oncol. 23(6), 1549-1555 (2012
13. Swanton C, Larkin JM, Gerlinger M et al. Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasets. Genome Med. 2(8), 53 (2010
14. Kaelin WG Jr. The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma. Clin. Cancer Res. 13(2 Pt 2), 680s-684s (2007
15. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 373(9669), 1119-1132 (2009
16. Toschi A, Lee E, Gadir N, Ohh M, Foster DA. Differential dependence of hypoxiainducible factors 1 a and 2 a on mTORC1 and mTORC2. J. Biol. Chem. 283(50), 34495-34499 (2008
17. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 12(1), 9-22 (2007
18. Sabatini DM. mTOR and cancer: Insights into a complex relationship. Nat. Rev. Cancer. 6, 729-734 (2006
19. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM. Phosphorylation and regulation of Akt/PKB by the rictor- TOR complex. Science 307(5712), 1098-1101 (2005
20. Sarbassov DD, Ali SM, Sengupta S et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell. 22, 159-168 (2006
21. Zeng Z, Sarbassov dos D, Samudio IJ et al. Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML. Blood 109(8), 3509-3512 (2007
22. Ebos JM, Lee CR, Kerbel RS. Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy. Clin. Cancer Res. 15(16), 5020-5025 (2009
23. Hutson TE, Bukowski RM, Cowey CL, Figlin R, Escudier B, Sternberg CN. Sequential use of targeted agents in the treatment of renal cell carcinoma. Crit. Rev. Oncol. Hematol. 77(1), 48-62 (2011
24. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl Cancer Inst. 92(3), 205-216 (2000
25. Jänne PA, Gray N, Settleman J. Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat. Rev. Drug Discov. 8(9), 709-723 (2009
26. Gossage L, Eisen T. Targeting multiple kinase pathways: A change in paradigm. Clin. Cancer Res. 16(7), 1973-1978 (2010
27. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat. Rev. Cancer 8(8), 592-603 (2008
28. Zhang L, Chang W, Sun B, Groh M, Speicher A, Lou H. Bisbibenzyls, a new type of antifungal agent, inhibit morphogenesis switch and biofilm formation through upregulation of DPP3 in Candida albicans. PLoS ONE 6(12), e28953 (2011
29. Loges S, Mazzone M, Hohensinner P, Carmeliet P. Silencing or fueling metastasis with VEGF inhibitors: Antiangiogenesis revisited. Cancer Cell 15(3), 167-170 (2009
30. Huang D, Ding Y, Zhou M et al. Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res. 70(3), 1063-1071 (2010
31. Wysocki PJ. mTOR in renal cell cancer: Modulator of tumor biology and therapeutic target. Expert Rev. Mol. Diagn. 9(3), 231-241 (2009
32. Heng DY, Mackenzie MJ, Vaishampayan UN, Bjarnason GA, Knox JJ. Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: Clinical characteristics, risk factors, and subsequent therapy. Ann. Oncol. 23(6), 1549-1555 (2011
33. Albiges L, Lacovelli R, Porta C et al. Prognosis of patients with metastatic renal cell carcinoma (mRCC) with primary resistance to sunitinib in metastatic renal cell arcinoma: Is there any active treatment? Eur. J. Cancer 47(Suppl. 1), (2011) (Abstract 7143
34. Busch J, Seidel C, Weikert S et al. Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma. BMC Cancer 11, 295 (2011
35. Banumathy G, Cairns P. Signaling pathways in renal cell carcinoma. Cancer Biol. Ther. 10(7), 658-664 (2010
36. Brannon AR, Rathmell WK. Renal cell carcinoma: Where will the state-of-the-art lead us? Curr. Oncol. Rep. 12(3), 193-201 (2010)